Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall

Kardiologiya

Volumn 47, Issue 2, 2007, Pages 25-30

  Susekov, A V ^a   Rozhkova, T A ^a   Tripoten, M I ^a   Pogorelova, O A ^a   Kulev, B D ^a   Balakhonova, T V ^a   Zubareva, M Yu ^a   Masenko, V P ^a   Rogoza, A N ^a   Kukharchuk, V V ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Atherosclerosis; Atorvastatin; Dyslipidemia; Endothelial function; Ischemic heart disease; Low density lipoprotein cholesterol; Vascular wall; Vascular wall distensibility

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; BLOOD VESSEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PYRROLES;

EID: 34247191187     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sacks F.N., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996;335:1001-1009.
2. The long-term prevention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary. Heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
4. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;3;291:9:1071-1080.
5. Nawrocki J. W., Weiss S.R., Davidson M.N. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Anerioscler Thromb Vasc Biol 1995;15:678-682.
6. Schwartz G.G., Ollson A.C., Ezekowitz M.D. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACLE) study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial, JAMA 2001;285:13:1711-1718.
7. Cannon C.P., Braunwald E., McCabe C.H. et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
8. Collhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:9435:685-696.
9. Sever P.S., Dahlof B., Poulter N.R. et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm.(ASCOT -LLA): a Multicentre controlled lipid-lowering trial. Lancet 2003;361:1149-1158.
10. LaRosa J.C., Grundy S.M., Waters D.D. et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:14:1425-1435.
11. Pedersen T.R., Faergeman O., Kastelein J.J.P. et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:19:2437-2445.
12. Amarenco P., Bogousslavsky J., Callahan A.III et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) invesigators. High-dose atorvastatin after stroke Or transient ischemic attack. N Engl J Med 2006;355:6:613-615.
13. Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabet Care 2006;29:6:1220-1226.
14. Knopp R.H., d'Emden M., Smilde J.G., Pocock S.J. Efficacy and safety in the prevention of cardiovascular end-points in subjects with type 2 diabetes:the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabet Care 2006;29:7:1478-1485.
15. Jones P., Kafonek S., Laurora I. et al. for the CURVES Investigator. Comparative dose efficacy study of atorvastatin vesus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES Study). Am J Cardiol 1998;81:3:583-587.
16. Russian source
17. Simons L.A., Sullivan D., Simons J., Celermajer D.S. Effect of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endohelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 1998;137:197-203.
18. Marchesi S., Lupatteli G., Siepi D. et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovascular Pharmacol 2000;36:5:617-621.
19. Russian source
20. Hosokawa S., Hiasa Y., Tomokane T. et al. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006;29:8:357-362.
21. Huptas S., Geiss H. C., Otto C., Parhofer K. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006;98:1:66-69.
22. Ray K. K., Cannon C. P., Cairns R. et al. PROVE IT-TIM] 22 investigators. Relationship between uncontrolled risk-factors and C- reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005:46:8:1417-1424.
23. Souza-Costa D.C., Sandrim V.C., Lopes L.F. et al. Anti-inflammatory effects of atorvastatin:modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2006.
24. Mason R.P., Walter M.F., Day C.A., Jacob R.F. Active metabolite of atorvastatin inhibits memrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 2006;281:14:9337-9345.
25. Russian source
26. Susekov A., Zubareva M., Solovieva E. et al. Treatment with statins and attainment of LDL-C goals in CHD patients with hyperlipideamia: main results of the Moscow Statins Survey (MSS). Atherosclerosis 2006;7:3: Suppl:116.
27. Russian source
28. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
29. Gamble G.D., Beaumont B., Smith H. et al B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histologic measurements. Atherosclerosis 1993;102:163-173.
30. Hirai T., Sasayama S., Kawasaki T., Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989;80:1:78-86.
31. Ridker P.M., Morrow D.A., Rose L.M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l:an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005;45:10:1644-1648.
32. Taneva E., Borucki K., Wiens L. et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006;97:7:1002-1006.
33. Brown S.L., Raal F.J., Panz, V.R. et al. High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J South Afr 2004;15:2:70-75.
34. Hsu H. Y., Wang P. Y., Chen Y. T. et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients. J Chin Med Ass 2005;68:2:53-58.
35. Ubels F.L., Muntinga J.H., van Doormaal J.J. et al. Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis 2001;154:1:155-161.
36. Karter Y., Curgunlu A., Erturk N. et al. Effects of low and high doses of atorvastatin on arterial compliance. Jpn Heart J 2003;44:6:953-961.
37. Kurpesa M., Tyminski M., Trzos E. et al. Influence of prolonged statin therapy on the arterial distensibility in stable ischemic heart disease. Przegl Lek 2005;62:4:210-213.
38. Smilde T.J., van den Berkmortel F.W., Wollersheim H. et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000;30:6:473-480.
39. Susekov A., Kulev B., Zubareva M. et al. Effect of simvastatin 20 and 80 mg/day on vascular function and structure in CHD patients with Familial Hypercholesterolaemia. Final results of the ESCAPE Study. Circulation 2006; Suppl.